TY - JOUR
T1 - Auraptene, an Alkyloxylated Coumarin from Citrus natsudaidai HAYATA, Inhibits Mouse Skin Tumor Promotion and Rat Colonie Aberrant Crypt Foci Formation
AU - Murakami, Akira
AU - Kuki, Wataru
AU - Takahashi, Yasuo
AU - Yonei, Hiroshi
AU - Tanaka, Takuji
AU - Makita, Hiroki
AU - Wada, Keiji
AU - Ueda, Naomi
AU - Haga, Masanobu
AU - Nakamura, Yoshimasa
AU - Ohto, Yoshimi
AU - Kim, Oe Kyung
AU - Ohigashi, Hajime
AU - Koshimizu, Koichi
PY - 1998
Y1 - 1998
N2 - Auraptene, a coumarin-related compound, has been isolated from the cold-pressed oil of natsumikan (Citrus natsudaidai HAYATA), as an inhibitor of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced Epstein-Barr virus (EBV) activation in Raji cells. In a two-stage carcinogenesis experiment with 1.6 nmol of TPA and 0.19 μmol of 7,12-dimethyl benz[a]anthracene (DMBA) in ICR mouse skin, topical application of 160 nmol of auraptene significantly reduced tumor incidence and the number of tumors per mouse by 27% and 23%, respectively. Auraptene at 50 μM almost completely suppressed TPA-induced superoxide (O2-)and hydroperoxide (ROOH) generation in differentiated HL-60 cells as well as lypopolysaccharide (LPS)/interferon-γ(IFN-γ)-induced nitric oxide (NO) generation in RAW 264.7 cells. Dietary feeding of auraptene at a dose of 100 or 500 ppm inhibited azoxymethane (AOM)-induced rat colonic aberrant crypt foci (ACF) formation in a dose-dependent manner. Oral administration of auraptene (50 - 200 mg/kg body wt.) clearly enhanced the glutathione S-transferase (GST) activity in mouse liver, suggesting that auraptene is an effective chemopreventer in both tumor initiation and promotion phases.
AB - Auraptene, a coumarin-related compound, has been isolated from the cold-pressed oil of natsumikan (Citrus natsudaidai HAYATA), as an inhibitor of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced Epstein-Barr virus (EBV) activation in Raji cells. In a two-stage carcinogenesis experiment with 1.6 nmol of TPA and 0.19 μmol of 7,12-dimethyl benz[a]anthracene (DMBA) in ICR mouse skin, topical application of 160 nmol of auraptene significantly reduced tumor incidence and the number of tumors per mouse by 27% and 23%, respectively. Auraptene at 50 μM almost completely suppressed TPA-induced superoxide (O2-)and hydroperoxide (ROOH) generation in differentiated HL-60 cells as well as lypopolysaccharide (LPS)/interferon-γ(IFN-γ)-induced nitric oxide (NO) generation in RAW 264.7 cells. Dietary feeding of auraptene at a dose of 100 or 500 ppm inhibited azoxymethane (AOM)-induced rat colonic aberrant crypt foci (ACF) formation in a dose-dependent manner. Oral administration of auraptene (50 - 200 mg/kg body wt.) clearly enhanced the glutathione S-transferase (GST) activity in mouse liver, suggesting that auraptene is an effective chemopreventer in both tumor initiation and promotion phases.
UR - http://www.scopus.com/inward/record.url?scp=0347024111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0347024111&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0347024111
SN - 0097-6156
VL - 701
SP - 86
EP - 95
JO - ACS Symposium Series
JF - ACS Symposium Series
ER -